There are a lot of things happening right now in the cancer research industry. Among the many companies within the field, there are few that stand out. Seattle Genetics is one of the few. CEO and co-founder Clay Siegall has created an innovative company whose stock price has tripled over a five-year span.
Dr. Siegall has been in the industry for decades. After receiving his Ph.D. from George Washington University, he began working for Bristol-Myers Squibb Pharmaceutical Research Institute as a Senior Research Investigator. He was eventually promoted to Principal Scientist before moving on to the National Cancer Institute as a Staff Fellow. After his experience at the National Cancer Institute, he branched out on his own.
Clay Siegall helped launch Seattle Genetics in 1998. Since its founding, he has been endlessly committed to leading the company to achieve great advancements within the cancer research field. He was elected to become Seattle Genetics’ CEO in 2002, currently sitting as its CEO, President, and chairman of the board.
Seattle Genetics has found success in innovative research developments, guided by their desire to help patients alleviate their suffering. With Dr. Siegall’s leadership, Seattle Genetics has reached completely new levels of research advancement, developing the first ADCs (antibody-drug conjugates). ADCETRIS received FDA approval in 2011, expanding exponentially throughout more than 60 countries.
Dr. Siegall’s commitment to the company and to patients is a true testament to who he is as a person, an integral part of ensuring ADCETRIS’ FDA approval. He also leads the way in fundraising, helping to secure more than $1.2 billion in both private and public funding for the company. Without his help, Seattle Genetics would not have been able to accomplish their dream of paving the way in cancer treatment advancements.
An accomplished man, Clay Siegall has received numerous awards for his leadership. Among the awards he has received is the Pacific Northwest Ernst & Young Entrepreneur of the Year and the University of Maryland Alumnus of the Year. He is an accomplished, published author with more than 70 articles published. He is always looking towards the future in innovative technology, holding more than 15 patents.